DOCSLIB.ORG

Long-Term Investment Lonza’S Aim Is Continuous Growth with Above-Average Profitability

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Long-Term Investment Lonza’S Aim Is Continuous Growth with Above-Average Profitability 9/2007 9/2007SeptemberSeptember Management Production Shareholders Pay The N ewsPa P e r Enthusiasm for New Tech- for Return nologies – Ultrasonic Level on Assets for T he chemical aN d Measurements in Decline? Page 4 life scieN ces markeT s Page 21 Powered BY Long-term Investment Lonza’s Aim is Continuous Growth with Above-average Profitability y making several changes, Lonza strengthen our microbial bio- At the end of July, you present- S. Borgas: By taking over the tech business and help to extend ed a strategy for this business bio-pharma business of Cam- has focused its portfolio on Lonza’s leading position as a area. Could you explain this brex, we have strengthened the life-sciences market. After custom manufacturer. The oth- briefly? our existing microbial busi- B er one will form an independent ness and, in 2007, Lonza was previously divesting itself of its special Newsflow business unit for us under the S. Borgas: Our aim is to the market leader in microbial portfolio and chemical/industrial chem- name of Lonza Bioscience. position Bioscience as the lead- bio-pharmaceutics. In addition Ineos completes Borealis deal. Fol- ing supplier of services and bio to our large- and small-scale ical business, the Swiss company took lowing clearance by the European Lonza Bioscience, the larger of materials for the life-sciences existing capacity in Visp, Swit- Commision, Ineos has completed over the bio areas of the US-company the businesses purchased from industry. Lonza’s new business zerland, we have gained fur- the purchase of the Borealis petro- Cambrex, is a new business area area completely met all of our ther medium- and small-scale Cambrex in February 2007. So this year, chemicals business in Norway for for Lonza. What expectations do expectations in the first half production capacity as well as €290 million. The business includes for the first time, life sciences make up you have? of 2007 and, after excluding skills in the field of bio-pharma a 50 % interest in the Noretyl ethylene short-term integration costs, services. We have already re- over 90 % of the total turnover. Birgit cracker at Rafnes and three polyole- S. Borgas: Lonza Bioscience achieved a high margin. The vised our strategy for this area fin plants based at the nearby Bamble Megges and Michael Reubold asked deals in specialised consum- integration is running to plan. and communicated this in mid site. The cracker was commissioned in er goods for bio-production, We have divided Bioscience into May. Stefan Borgas, CEO of Lonza, about the 1977 and expanded by 100,000 t/a in such as media, serums, cell four business units: cell therapy, We will consolidate our US 2005, and currently has a capacity of integration of the new business areas cultures, analytical test kits and rapid testing systems, media, activities in this field in Hop- 557,000 t/a in addition to a propylene so on. Then there is the classic and cell discovery & molecular kinton, Massachusetts. This will and the strategy behind concentrating capacity of 80,000 t/a. contract manufacturing busi- biology. In order to ensure the take place in close collaboration E www.ineos.com on the life science markets. ness in a brand new technology: development of the bioscience and with the full agreement of cell therapy. Here we grow new business, we intend to open up our customers. We will addition- Cognis to sell Pulcra. Shortly after CHEManager Europe: Mr Borgas, therapeutics that in 5 – 10 years new business areas and access ally invest over US$30 million in separating the process chemicals Lonza took over the bio areas of will perhaps be able to cure some very promising technology Hopkinton, in order to support business from the core business Cog- Cambrex six months ago. What illnesses such as Parkinson’s platforms. our plans for growth in produc- nis is intensifying efforts to divest the was the strategy behind this or bone marrow incompatibil- tion and microbial process de- division, which is called Pulcra since acquisition? ity that have so far remained How will the area of microbial velopment. Through this expan- July 1. In order to find a partner or an untreatable. And Lonza would bio-pharmaceutics be organised sion we will be able to create up investor, Cognis has hired the M&A S. Borgas: We took over two ar- then be there as a production in the future, and how are you to 250 additional jobs. specialist Lincoln. Pulcra had sales eas from the American compa- Stefan Borgas expert, which is a further option integrating these locations into of €258 million in 2006 and has ny Cambrex. The first one will CEO of Lonza for the future. your existing business? E Continues Page 11 production sites or service centers in germany, Turkey, Italy, Spain, Mexico, Brazil, China, India, Indonesia and the US. Pulcra’s products are mainly used in the textile and leather industries. Competence And Dedication Rules Of The Game E www.cognis.com Bayer to withdraw from NYSE. Bayer In Custom Manufacturing Size is Not All that Matters Distribution of Pharma Chemicals Requires Expertise follows Ciba, BASF and Eon as all com- panies are delisted from the New York r. Karl-Gerhard Seifert, who Reubold asked him about his ith external sales of Brenntag manage the Stock Exchange. The company expects € successful coexistence of some €15 million annual savings. The has been working in the strategies for AllessaChemie 6.1 billion in 2006 two such different fields management expects the delisting by chemical industry for 35 and AllessaSyntec, and how and over 300 sites as commodities and phar- early October. W maceutical chemicals? D E www.bayer.com years, resigned from his function as he appraises the current situ- around the world, Brenntag is a lead- Managing Director for AllessaChemie ation of the global fine chemi- ing international company in the dis- W. Gierling: Brenntag’s OM Group buys Borchers. North many years of experi- American OM Group will buy additive in January. He is now an “active chair- cals industry. tribution of industrial and speciality ence with pharmaceuti- specialist Borchers from Lanxess. The man”, who discusses the strategy and cals customers in Europe transaction is due to the agreement chemicals. Building on its considerable CHEManager Europe: Dr. enables us to identify of German authorities. The closing future development of the company Seifert, you have been a market penetration in basic chemicals, customers’ needs well in of the deal is expected for the end with the managing directors. He is also driving force during both advance and offer serv- of September. Borchers employs 90 Brenntag is now focusing on its spe- management buy-outs, ices to optimise sourcing people and had total sales of €36 a member of the Advisory Board of which have resulted in ciality chemicals business in Europe, and production proc- million in 2006. AllessaSyntec. Dr. Seifert played an the formation of Alles- esses. With regard to E www.lanxess.com saChemie in the year and the field of pharmaceuticals is basic chemicals, we al- active role in the management buy- 2001 and AllessaSyntec in ready offer tailor-made Nestlé integrates Gerber. Nestlé fin- one of the strategic growth segments. outs (MBOs) leading to the creation of 2004. What has been the solutions for many of ishes the acquisition of US baby food starting position in both Michael Reubold asked Wilhelm Gier- our customers: in terms company Gerber after all government both companies. He combines a distin- cases, and were those of specifications, pack- authorities agreed. Nestlé acquired ling, European Business Development guished track record in international comparable? age size, labelling and Gerber from Novartis in April for US- Dr. Karl-Gerhard Seifert Wilhelm Gierling Chairman of AllessaChemie and member of Manager Pharma at Brenntag’s Ger- European Business Development Manager documentation, right up $5.5 billion. Nestlé is quickly looking senior management in the chemical the Advisory Board of AllessaSyntec K.-G. Seifert: The start- Pharma at Brenntag to disposal and auditing to integrate the new business, which industry and an excellent knowledge ing positions were simi- man central office in Muelheim/Ruhr of the manufacturer. For includes 4,500 employees. The take- lar, but not completely compa- CHEManager Europe: Mr. Gier- customers who require support over was effective September 1. of global finance and investment glomerate Hoechst AG (1988 – 1997), about the strategy for expanding their rable. AllessaChemie had been ling, in the distribution of with the synthesis of active in- E www.nestle.com environment. Prior to Allessa, he as CEO of Clariant (1997 – 1999) and formed in 2001 mainly as a cus- pharmaceuticals business, and the par- chemicals, there are very few gredients or want assistance tom manufacturing company full-line distributors with a bal- in developing formulations, we served as a member of the Board of head of Morgan Grenfell Private Equi- ticular demands this market makes on anced portfolio of industrial and Management of former German con- ty Ltd, Germany (1999– 2000). Michael E Continues Page 9 chemicals distributors. speciality chemicals. How does E Continues Page 14 e reader service Aliphatic CF3 Building Blocks: Any Scale, any Time! don’t have your own Solvay Organics GmbH chemanager europe? Headquarters Buchenallee 20 D-51427 Bensberg, (Cologne) wrong address? Germany G· Fee paid · D 12264 paid · D 12264 G· Fee Tel: +49 2204 926-900 a [email protected] Send an e-mail at North American Sales Office · PF 11 05 64 · 64220 Darmstadt 05 64 · 64220 · PF 11 c/o Girindus Sales Corporation G chemanager-europe@ 8560 Reading Road Cincinnati gitverlag.com Ohio 45215, USA Solvay Tel: +1 513 679 3031 [email protected] Organics Pressepost · DP GIT Verla [email protected] Page 2 MARKETS & COMPANIES CHEManager Europe 9/2007 CONTENT Front Page Meeting Pharma’s Future Challenges .........................................................
Load more

Recommended publications
  • Technical Information
    Technical Information Antibiotic Assay Medium No.1 (Seed Agar) Product Code : DM1003 Application: - Antibiotic Assay Medium No.1 (Seed Agar) is used in the microbiological assay of beta-lactam and other antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 6.000 or detecting faecal coliforms drinking in water waste water, seawater and foods samples by MPN Method. Casein enzymic hydrolysate 4.000 Yeast extract 3.000 Beef extract 1.500 Dextrose 1.000 Agar 15.000 Final pH (at 25°C) 6.6±0.2 **Formula adjusted, standardized to suit performance parameters Principle & Interpretation The potency of an antibiotic can be determined by chemical, physical and biological methods. An assay is performed to determine the ability of an antibiotic to kill or inhibit the growth of living microorganisms. Biological tests offer the most convenient m eans of performing an assay (1), since a reduction in the antimicrobial activity of a specific antibiotic reveals changes that is not usually displayed by chemical methods (2). Antibacterial susceptibility testing may be performed by either dilution (turbidimetric) or diffusion methods. The choice o f methodology is based on many factors, including ease of performance, flexibility and use of automated or semi-automated devices for both identification and susceptibility testing (3). Grove and Randall have elucidated antibiotic assays and media in their comprehensive treatise on antibiotic assays (4). Antibiotic Assay Medium No.1 is used in the microbiological assay of ß-lactam and other antibiotics. These media are prepared according to the specifications detailed in various pharmacopoeias (2-6) and by the FDA (7).
    [Show full text]
  • Contractor Orientation Manual
    Contractor Orientation Manual KALAMAZOO CONTRACTOR ADMINISTRATION TABLE OF CONTENTS INTRODUCTION......................................................................................................................................4 DEFINITIONS...........................................................................................................................................4 1. Supplier: ........................................................................................................................................4 2. Contractor: ………………………………………………………………………………………4 3. Pfizer Contact: ...…………………………………………………………………………….4 4. Kalamazoo Contractor Administration: ……………………………………………………..4 GENERAL INFORMATION....................................................................................................................5 1. Company Access ...........................................................................................................................5 2. Vehicle Admittance & Parking .....................................................................................................5 3. Tobacco Products ..........................................................................................................................6 4. Cafeterias and Snack Bars..............................................................................................................6 5. The Federal Food, Drug and Cosmetic Act................................................................................... 6 6. Good Manufacturing Practices
    [Show full text]
  • Custom Manufacturing in Thailand, Evonik in China
    10/2011 October Markets and Companies Markets and Companies Interview with Styrolution’s CEO THE NEWSPAPER FOR THE Expert Peter Pollak discusses the Roberto Gualdoni CHEMICAL AND fragmented world of fine chemicals Page 5 LIFE SCIENCE MARKE TS Pages 8 and 14 N EWSFLOW Market and Companies: Haltermann sold to H.I.G Europe, Dr. Uwe Nickel named new CEO. An Industry Full of Opportunity DuPont seeking buyers for two se- parate businesses: a polyester-film CPhI Highlights the Latest Trends in Pharma joint venture and one that makes powder-based paint. Bayer and Yunona Holdings have entered a memorandum of under- Markus Blocher Dr. Jörn Winterfeld standing to manufacture drugs in CEO, Dottikon Russia. Director Business Line Pharma/Agro at Wacker Biosolutions, Wacker AstraZeneca has announced it will be laying off about 400 employees in the U.S., primarily at its head- API Fine Chemicals quarters in Wilmington, Del. … Chemical exclusive synthesis partners Consolidation in the fine chemicals industry Lanxess has announced three in- need to possess a versatile technology will continue, since it is a very fragmented vestments totaling upwards of €30 “ portfolio like a Swiss army knife and be as industry. Many small players may vanish million in Brazil. ” “ ” precise and reliable as a Swiss watch. or merge to attain the so-called critical mass. Syngenta has posted a 21 % rise in This trend includes producers in China. its Q3 results over last year. More on Page 2 ▶ Jean Bléhaut Director of Marketing & Business Development, Novasep Dr. Martin Wienkenhöver Under Construction: CEO, CABB Both Solvay and Evonik are building hydrogen peroxide plants; Solvay Custom Manufacturing in Thailand, Evonik in China.
    [Show full text]
  • Evolution of a Regulatory Framework for Pharmaceuticals Derived from Genetically Modified Plants
    Review Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants Armin Spo¨k1*, Richard M. Twyman2, Rainer Fischer3, Julian K.C. Ma4 and Penelope A.C. Sparrow5* 1 Inter-University Research Centre for Technology, Work and Culture (IFZ), Schlo¨ gelgasse 2, A-8010 Graz, Austria 2 Department of Biology, University of York, Heslington, York, YO10 5DD, UK 3 Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany 4 St George’s Hospital Medical School, Cranmer Terrace, London, SW17 0RE, UK 5 John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK The use of genetically modified (GM) plants to synthes- phase II clinical trials, respectively [6]. In 2006, the United ize proteins that are subsequently processed, regulated States Department of Agriculture (USDA) licensed a poul- and sold as pharmaceuticals challenges two very differ- try vaccine produced in cultured tobacco cells [7]. Since ent established regulatory frameworks, one concerning then, several products derived from crop plants have also GM plants and the other covering the development of reached late development stages, including human insulin biotechnology-derived drugs. Within these regulatory and carp growth hormone produced in safflower. These are systems, specific regulations and guidelines for plant- expected to reach the market between 2008 and 2010 (see made pharmaceuticals (PMPs) – also referred to as plant- Table 1). derived pharmaceuticals (PDPs) – are still evolving. The PMPs present two major challenges for the regulatory products nearing commercial viability will ultimately bodies. Regulators of agricultural biotechnology are con- help to road test and fine-tune these regulations, and fronted with a novel type of crop use, and drug regulators might help to reduce regulatory uncertainties.
    [Show full text]
  • New Deals, New Investments in Chemical Manufacture
    Chemical Manufacture New deals, new investments in chemical manufacture We review some of the most recent contracts, investments and merger and acquisition activities in the highly competitive field of fine chemical manufacture. he manufacture of pharmaceutical fine chemical business is a major player in the global fine chemical sector, intermediates and ingredients remains probably the with a leading position in the supply of contract manufacturing Tmost competitive sector of the chemical industry and services to the agrochemicals, pharmaceutical and speciality there continue to be major changes in the structure of the chemical industries. The acquisition included all Avecia Fine sector and in the geographical spread of major manufacturing Chemicals’ assets and operations on the 65 hectare site at faciltiies, with investments in China and India playing a leading Grangemouth, UK. All 310 Avecia Fine Chemicals’ employees part in companies’ moves to acquire stronger positions. This were included in the transaction. In 2004, the business article looks at just a few of the recent developments. recorded sales of £38 million. Avecia Fine Chemicals Limited now operates as KemFine UK Acquisition of ozone chemistry technology Ltd. Tom Shields is the managing director, and is based at the In February, Dishman Pharmaceuticals & Chemicals Ltd Grangemouth site. KemFine, previously Kemira Fine Chemicals acquired IO3S Ltd of Bern, Switzerland, through its 100% Oy, was created via an MBO of the business from Kemira in wholly owned Switzerland based subsidiary company M/s. 2004. 3i, a world leader in the private equity and venture Dishman Switzerland Ltd. The Assets base of IO3S is currently capital sector, supported the management team in the about $2 million but Dishman says the acquisition was transaction and in the equity funding.
    [Show full text]
  • Chemacx Vendor List
    ChemACX Vendor List -A B C D E F G H I J K L M N O P Q R S T U V W X Y Z- -#- APAC PHARMACEUTICAL ACTIVATE SCIENTIFIC GMBH AQCHEM LLC ADESIS INC. 1K SCIENTIFIC ASW MEDCHEM, INC. ADVAMACS 3A PHARMATECH AURUM PHARMATECH LLC ADVANCE RESEARCH CHEMICALS, INC. 3B SCIENTIFIC CORP. AARON CHEMISTRY ADVANCED AROMATICS, L.P. 3RCHEM ABAMACHEM LTD ADVANCED ASYMMETRICS, INC. 8S LABORATORIES LLC ABBEY COLOR ADVANCED CHEMBLOCKS INC. Updated Aug. 2018 -A- ABBOTT LABORATORIES CHEMICAL DIVISION ADVANCED CHEMTECH A&A LIFE SCIENCE INC. DBA ABBY PHARMATECH LLC ADVANCED MOLECULAR AVACHEM SCIENTIFICS TECHNOLOGIES PTY LTD ABERJONA LABORATORIES A&C PHARMTECH, INC ADVANCED SCIENTIFIC ABOVCHEM LLC INTERNATIONAL, LLC A&J PHARMATECH ABSOLUTE CHIRAL ADVANCED SYNTHESIS A.G. SCIENTIFIC Updated July 2018 TECHNOLOGIES, S.A. Updated Jan. 2018 ACADECHEM COMPANY LIMITED ADVANCED TECHNOLOGY & A1 BIOCHEM LABS INDUSTRIAL CO., LTD. Updated Sep. 2018 ACADEMIQUE PHYTOCANADA AIMS FINE CHEMICALS INC. AA BLOCKS LLC ACCELA CHEMBIO CO., LTD. New Sep. 2018 Updated June 2018 AIR PRODUCTS & CHEMICALS, INC. AB CHEM TECHNOLOGIES LLC ACCELEDEV CHEMICAL LLC AJINOMOTO - AMINO ACID DEPARTMENT ABCR GMBH & CO. KG ACCUSTANDARD, INC. ALBANY MOLECULAR RESEARCH, INC. ABSCO LTD ACE SYNTHESIS LLC ALBEMARLE CORPORATION ABX ADVANCED BIOCHEMICAL ACENTEX SCIENTIFIC, INC. COMPOUNDS ALBRIGHT & WILSON AMERICAS ACESYS PHARMATECH AECHEM ALCHEM INTERNATIONAL LIMITED ACETO CORPORATION AK SCIENTIFIC, INC. ALCHEM PHARMTECH, INC. Updated Sep. 2018 ACHEMICA ALDLAB CHEMICALS, LLC AKL RESEARCH LLP ACINOPEPTIDE CO. LTD ALDRICH AOBCHEM USA ACME BIOSCIENCE, INC. ALFA AESAR AOKBIO CO., LTD ACROS ORGANICS Updated Apr. 2018 ALFA CHEMISTRY ACROS ORGANICS – USA New June 2018 AOKCHEM CO., LTD.
    [Show full text]
  • A Fine Art How Much of the Fin E Chemicals Market Can Pharma Lay Claim to Today- and in the Future? Jan Ramakers, Jan Ramakers Fine Chemical Consulting Group Writes
    E CHEMICALS • A fine art How much of the fin e chemicals market can pharma lay claim to today- and in the future? Jan Ramakers, Jan Ramakers Fine Chemical Consulting Group writes ine chemicals, speciality chemicals, and performance chemicals are some of the various names used to describe products in the Fine chemical market in 2014 Fhigh-value end of the chemical market. In order to avoid any - total value $127.7bn - confusion, it is good to keep in mind that fine chemicals ore defined as (high value) chemical products that ore sold for what they ore, ie for Other Pharma their precise chemical structure. Speciality chemicals, often also referred Food a to as performance chemicals, are (high value) chemical products that 4% ore sold for what they do. So an intermediate used in the manufacture Pigments& of a specific API is a fine chemical as it needs to have a very specific 3% chemical structure; a different chemical structure cannot be used. Fine chemicals are used across a wide range of market segments, and it is easy enough to make a list that features 40-50 different application intermediates areas. 10% The products end up in speciality chemicals markets, for instance as Fragrances active ingredients in biocide formulations, as additives for plastics and 7% coatings, or as active ingredients in cosmetics and toiletries. Some are Figure 1. used as intermediates in the manufacture of liquid crystal displays, and so on. Many of those end markets are quite large, but most of them are fairly small as an outlet for fine chemicals.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0122887 A1 Klopprogge Et Al
    US 2007.0122887A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0122887 A1 Klopprogge et al. (43) Pub. Date: May 31, 2007 (54) GENE VARIANTS CODING FOR PROTEINS (30) Foreign Application Priority Data FROM THE METABOLIC PATHWAY OF FNE CHEMICALS Dec. 18, 2003 (DE)..................................... 103 59 661.5 (75) Inventors: Corinna Klopprogge, Mannheim (DE); Publication Classification Oskar Zelder, Speyer (DE); Burkhard Kroger, Limburgerhof (DE); Hartwig (51) Int. Cl. Schroder, Nublock (DE); Stefan CI2P I3/04 (2006.01) Haefner, Ludwigshafen (DE); Uwe CI2P I3/08 (2006.01) Ruffer, Meckenheim (DE); Claudia C7H 2L/04 (2006.01) Isabella Graef, Lampertheim (DE) CI2N 9/10 (2006.01) CI2N 15/74 (2006.01) Correspondence Address: CI2N I/2 (2006.01) LAHIVE & COCKFIELD, LLP ONE POST OFFICE SQUARE (52) U.S. Cl. ......................... 435/106; 435/115; 435/193; BOSTON, MA 02109-2127 (US) 435/252.3; 435/471; 536/23.2 (73) Assignee: BASF Aktiengesellschaft, Ludwigshafen (DE) (57) ABSTRACT (21) Appl. No.: 10/583,404 (22) PCT Filed: Dec. 16, 2004 The present invention relates to mutated nucleic acids and proteins of the metabolic pathway of fine chemicals, to (86). PCT No.: PCT/EPO4/14338 processes for preparing genetically modified producer organisms, to processes for preparing fine chemicals by S 371(c)(1), culturing said genetically modified organisms and to said (2), (4) Date: Jun. 16, 2006 genetically modified organisms themselves. US 2007/O 122887 A1 May 31, 2007 GENEVARLANTS CODNG FOR PROTEINS FROM and optimized C yield, there is a constant need for further THE METABOLIC PATHWAY OF FINE improving the productivity of said organisms.
    [Show full text]
  • Fine Chemical Intermediates
    Fine Chemical Intermediates On Request (OR) / Main Structure Identification Characteristics Regular Applications Production (RP) Phosgene derivatives Methyl chloroformate Assay: min. 99% by area Organic reagent for RP O MCF, Methyl chlorocarbo- introduction of the nate, Chloroformic acid Appearance: colourless to methoxycarbonyl methyl ester pale yellow liquid group, synthesis of Packaging: 160 kg drum, carbonates, Cl O CAS Reg. No. 79-22-1 ISO tank carbamates, anhydrides etc. Ethyl chloroformate Assay: min. 98.5% by area Organic reagent for RP O ECF, Ethyl introduction of the chlorocarbonate, Appearance: colourless to ethoxycarbonyl group, Chloroformic acid ethyl pale yellow liquid synthesis of ester Packaging: 160 kg drum, carbonates, Cl O ISO tank carbamates, CAS Reg. No. 541-41-3 anhydrides etc. n-Propyl chloroformate Assay: min. 98% by area Organic reagent for OR O nPCF, n-Propyl chlorocar- introduction of the n- bonate, Chloroformic acid Appearance: colourless to propoxycarbonyl propyl ester pale yellow liquid group, synthesis of Cl O Packaging: ISO tank carbonates, CAS Reg. No. 109-61-5 carbamates, anhydrides etc. Isopropyl chloroformate Assay: min. 98.5% by area Organic reagent for OR O iPCF, 2- introduction of the Propylchloroformate, Appearance: clear colour- isopropoxycarbonyl Chloroformic acid less to pale yellow liquid group, synthesis of isopropyl ester Packaging: ISO tank carbonates, Cl O carbamates, CAS Reg. No. 108-23-6 anhydrides etc. n-Pentylchloroformate Assay: min. 98.5% by area Organic reagent for OR n-Pentylchlorocarbonate, introduction of the n- O Chloroformic acid pentyl Appearance: colourless pentoxycarbonyl ester liquid group, synthesis of Packaging: 190 kg drum carbonates, Cl O CAS Reg. No. 638-41-5 carbamates, anhydrides etc.
    [Show full text]
  • Cbn Smis Intervention of March 2, 2017 - Sales
    CBN SMIS INTERVENTION OF MARCH 2, 2017 - SALES S/N CUSTOMERS NAME AMOUNT (US$) RATE (N/US$) ITEM OF IMPORT FORM 'M' NUMBER LC NUMBER DATE OPENED MATURITY DATE BANK 45- DAY TENOR 1 SMSAM SYSTEM LTD 20,500.00 380.00 SOFTWARE MF20160100500 22157280377 UNITY 2 PROCTER AND GAMBLE NIGERIA LIMITED 52,623.11 375.00 KRAFT BLEACHED WOODPULP 25.0CM MF20160086965X 152.0CM 516 (RAW MATERIAL5067600865 FOR PRODUCING7/28/16 PAMPERS) 1/17/17 CITI 3 PROCTER AND GAMBLE NIGERIA LIMITED 92,391.70 375.00 KRAFT BLEACHED WOODPULP CMC530MF20160086945 (RAW MATERIAL FOR PRODUCING5063600865 PAMPERS)7/28/16 10/28/16 CITI 4 PROCTER AND GAMBLE NIGERIA LIMITED 89,851.22 375.00 BG PA BFLY S2 10 SMP SSA; BG PA SF BFLYMF20160095066 S2 80 JP SSA; BG PA SF 5064600890BFLY S4 64 JP8/16/16 SSA; BG PA SF BFLY S3 911/4/16 SMP SSA; BG PA SF BFLY S3CITI 72 JP SSA (RAW MATERIAL FOR PRODUCING PAMPERS) 5 PROCTER AND GAMBLE NIGERIA LIMITED 214,060.00 375.00 AQUALIC CA L521 (RAW MATERIAL FORMF20160091918 PRODUCING PAMPERS) 5069600877 8/8/16 11/28/16 CITI 6 PROCTER AND GAMBLE NIGERIA LIMITED 183,480.00 375.00 AQUALIC CA L521 (RAW MATERIAL FORMF20160094963 PRODUCING PAMPERS) 5063600890 8/16/16 11/28/16 CITI 7 PROCTER AND GAMBLE NIGERIA LIMITED 53,243.14 375.00 KRAFT BLEACHED WOODPULP 50.8CM MF20160095724X 120.0CM 516 (RAW MATERIAL5062600891 FOR PRODUCING8/17/16 PAMPERS) 10/28/16 CITI 8 PROCTER AND GAMBLE NIGERIA LIMITED 61,537.41 375.00 POLYESTER NONWOVEN ACQUISITIONMF20160093058 LAYER (43G/M2) AQL 2+ WHITE5061600876 80 MM (RAW8/8/16 MATERIALS FOR PRODUCING1/2/17 PAMPERS) CITI 9 PROCTER AND GAMBLE NIGERIA LIMITED 42,302.05 375.00 980 - U- TAPES 13MM WIDTH 13MM ADHMF20160086914 U GLUE 8 BOX/FUM.
    [Show full text]
  • Development of Simple and Efficient Synthetic Strategies For
    Tiina Saloranta Development of Simple and Efficient Synthetic Strategies for Production of Fine Chemicals of Pharmaceutical Relevance of Pharmaceutical Production of Fine Chemicals for Strategies Synthetic of Simple and Efficient Development Development of Simple and Efficient Synthetic Strategies for Production of Fine Chemicals of Pharmaceutical Relevance ‒ Metal‐Mediated Allylation Combined with Applied Catalysis Tiina Saloranta ISBN 978‐952‐12‐2743‐1 Laboratory of Organic Chemistry Painosalama Oy – Turku, Finland 2012 Department of Chemical Engineering Division of Natural Sciences and Technology Åbo Akademi University Åbo, Finland 2012 2012 Development of Simple and Efficient Synthetic Strategies for Production of Fine Chemicals of Pharmaceutical Relevance ‒ Metal‐Mediated Allylation Combined with Applied Catalysis Tiina Saloranta Laboratory of Organic Chemistry Department of Chemical Engineering Division of Natural Sciences and Technology Åbo Akademi University Åbo, Finland 2012 SUPERVISOR AND CUSTOS Professor Reko Leino Laboratory of Organic Chemistry Åbo Akademi University Åbo, Finland OPPONENT Professor Shū Kobayashi Department of Chemistry The University of Tokyo Tokyo, Japan REVIEWERS Professor Pavel Kočovský Department of Chemistry University of Glasgow Glasgow, United Kingdom and Professor Guy Lloyd‐Jones School of Chemistry University of Bristol Bristol, United Kingdom ISBN 978‐952‐12‐2743‐1 Painosalama Oy – Turku, Finland 2012 Helky laulu Auran rantain silmä kirkas salamoi, kaiu maine kauas kantain minkä kunto kansan voi! Täällä Suomen synnyinmuistot, täällä työn ja tiedon puistot virttä vapauden soi virttä vapauden soi. :,: Helky laulu, kaiu maine, virttä vapauden soi.:,: Auran rantamilla tähti syttyi päälle Suomenmaan, Auran rantamilta lähti onni maahan ihanaan: Kristinuskon, tiedon valta nosti heimot kaikkialta turvaks armaan synnyinmaan turvaks armaan synnyinmaan. :,: Helky laulu, kaiu maine, virttä vapauden soi.:,: Puhkes uudet tertut tuomeen, aika aatteet uudet toi, Auran rantamilta Suomeen koitti kirkas huomenkoi.
    [Show full text]
  • Development of Bio-Based Fine Chemical Production Through Synthetic Bioengineering Hara Et Al
    Redesign Design Computer Simulation Common Source Metabolic Data Artificial Metabolic Map Metabolic Engineering Substrate Gene Manipulation Co- Enzyme enzyme Heterologous Fine chemical expression Overexpression Enzymatic Microbial Down regulation Fine chemical Fine chemical Deletion Synthesis Fermentation Mutation Development of bio-based fine chemical production through synthetic bioengineering Hara et al. Hara et al. Microbial Cell Factories 2014, 13:173 http://www.microbialcellfactories.com/content/13/1/173 Hara et al. Microbial Cell Factories (2014) 13:173 DOI 10.1186/s12934-014-0173-5 REVIEW Open Access Development of bio-based fine chemical production through synthetic bioengineering Kiyotaka Y Hara1, Michihiro Araki1, Naoko Okai1, Satoshi Wakai1, Tomohisa Hasunuma1 and Akihiko Kondo2* Abstract Fine chemicals that are physiologically active, such as pharmaceuticals, cosmetics, nutritional supplements, flavoring agents as well as additives for foods, feed, and fertilizer are produced by enzymatically or through microbial fermentation. The identification of enzymes that catalyze the target reaction makes possible the enzymatic synthesis of the desired fine chemical. The genes encoding these enzymes are then introduced into suitable microbial hosts that are cultured with inexpensive, naturally abundant carbon sources, and other nutrients. Metabolic engineering create efficient microbial cell factories for producing chemicals at higher yields. Molecular genetic techniques are then used to optimize metabolic pathways of genetically and metabolically well-characterized hosts. Synthetic bioengineering represents a novel approach to employ a combination of computer simulation and metabolic analysis to design artificial metabolic pathways suitable for mass production of target chemicals in host strains. In the present review, we summarize recent studies on bio-based fine chemical production and assess the potential of synthetic bioengineering for further improving their productivity.
    [Show full text]